Bespoke In Silico Inotropy Prediction Morgan Morris*, Nathan Kidley*, Martin Slater*, Jeremy Billson**, Rob Scoffin* * Cresset, Cambridgeshire, UK morgan.morris@cresset-group.com www.cresset-group.com ** InoCardia, Coventry, UK jeremy.billson@inocardia.com www.inocardia.co.uk

Introduction

Inotropy – the ability of a compound to alter the force of cardiac muscle contraction – is a source of clinical and postclinical failure for many drug candidates. In vivo assays to detect inotropic agents may be supplemented with *in silico* models to conduct safety pharmacological screenings.

This poster describes *in silico* components of a bespoke analysis tool that identifies potential cardiac safety risk for candidate drug molecules. The tool incorporates, amongst other techniques, an *in silico* similarity analysis protocol to help detect potential inotropes as a pre-filter for selecting compounds to be confirmed by actual testing using InoCardia's innovative in-vitro rat myocyte assay.¹



Figure 1: InoCardia's nano-scale assay device which utilizes a single isolated cardiac myocyte to test the effects of new molecules on heart muscle contractility.

An ordered workflow (Figure 2) was envisaged for preselection for assay testing or deselection of candidates.



Figure 2: Workflow diagram introducing both ligand-centric and protein-centric techniques.

Method

The XED force field can be utilized to provide both accurate 3D geometries for molecules as well as an accurate assessment of their electrostatic fields, and the ways in which these fields would interact with, e.g., a biological target protein.² There are many applications of this technology in drug discovery, one of these being to generate a 'chemical space' for known drugs that can further be analyzed to identify regions of interest (for activity) or concern (for known side-effects, such as inotropy). The analysis was carried out by calculating a full N x N pairwise similarity matrix for a library of 2,200 known drugs, including 100 known inotropes. Up to 10 low energy conformers were generated for each molecule using the XED force field, and then the maximum similarity calculated for any pair of conformers of the two molecules.



Figure 3: Analyses of similarity matrices displaying therapeutics with similar targets.

The shape and molecular field similarity between pairs of conformers were calculated, and the best alignment and similarity for any given pair of molecule conformers was kept as the score for that pair. The matrix generated a chemical space that could be used to define inotrope potential as shown in Figure 3 (matrix clustered such that groups of similar molecules appear together on the leading diagonal).

This matrix was then analyzed by principal component analysis (PCA) to reduce graph dimensionality, and RF/ SVM/ ANN machine learning techniques were used to separate molecules based on relative position (Figure 4).

Another means of analysis is to project the N-dimensional similarity matrix into a lower dimensional space, e.g., a 2-D plot. This was done using a PCA which attempts to identify new 'dimensions' such that the maximum diversity in the data set is 'explained' by the first 'principal component', followed by the second, third, etc. By then plotting compounds using the first two PC's, we retrieved a new representation of 'chemical space' where molecules (points in the space) which were highly similar appeared close to one another.

This analysis (Figure 4) highlighted that inotropy can arise from multiple mechanisms, as is shown by the diverse spread of known inotropes within the space of known drug molecules. Hierarchical and fuzzy clustering were used to identify molecule groups based on similarity, and fuzzy clustering was used to further generate probabilities for 'Inotrope group' membership for individual molecules.



The diversity of structures and mechanisms leading to inotropy meant that we took a multi-faceted approach to identifying potential liability. Techniques utilized included similarity scoring, with the addition of a calculation of significance for the similarity result (using a z-score approach).

Compounds identified using the similarity screen were further assessed and confirmed/cleared using advanced techniques (Figure 5), such as docking to known target structures, or assessment using the Electrostatic Complementarity[™] (EC) component of Flare[™].³

Results and Visualization

Newly proposed structures were assessed for potential inotropy using similarity scoring to known inotropes and the comparison of these results with similarity to a broader set of known drugs (the majority of which do not show either positive or negative inotropy).



The results are highlighted in the case of the ion channel Nav 1.5 (PDB entry 6LQA) using a proposed bioactive conformation (Figure 5).

Docking results orthogonal to similarity scoring identified known B AR antagonist atenolol and negative inotrope flecainide as structurally similar hazard molecules. This is highlighted using Torx[®] (Figure 6).⁴

Further screening using the InoCardia work-loop model was thus avoided through in silico processing of the proposed lead compound.

From the results of the field similarities, the high similarity inotropes for a given mechanism were used together to generate multi-compound pharmacophores. This was then also used with inotropic activity data to generate QSAR models.

Figure 4: Drug space (PCA plot) showing known inotropes compared to 2,200 known drugs.

Figure 5: Proposed structure for new discovery project – similarity-based alert for potential Nav 1.5 activity confirmed by docking score.

| $F_{+}^{+} \circ f_{+}^{+} \circ f_{+$ | | | | Trocardia (Internal)-1 X Cardiac Safety Models Description of the predictions below are based on models of known Inotropes and the targets associated with inotropy, both positive and negative. The models use various computational chemistry techniques to make predictions: the main ones being: Similarity, Docking, Electrostatic Complementarity (EC) and 3D-C molecular similarity between your proposed structure and that of known inotropes is measured using Cresset's proprietary shape and electrostatic-based methods. Dor calculated using the LeadFinder algorithm from within Flare(tm). EC is also generated using the algorithms from Flare. 3D-QSAR models are generated based on the sim from Forge(tm) and these can provide a prediction of activity as well as a degree of coverage, i.e. what is the level of quality of the predictions. Current Selection SMILES: Coc1cce(OCC(F)(F)F)cc1(=0)NC[C@H]1CCC(C)C[NH2+]1 | | | |
|--|--|---|--|--|---|---|---|
| | F | ∑ N ^N ^H ₂ | Struct | ilarity ates the molecular similarity of a proposed struc for the similarity. i.e. what is the quality of the pro- | cture to those of known inotropes. Result ediction in terms of number of standard o | s are a raw similarity, a number betwe leviations away from an average simil | en 0.0 and 1.0, which is then transla arity. Higher is worse, a z-score abc |
| Besigns -1 X Idea, Review ∨ x □ TD-100341 | ∂ □ : | ОH | Clear Clear Clear Clear Inou Calcu inotro NOT S Calcu Ca | Anny a score acove s.o is very significant. App IED Similarity results Toggle Similarity results. Toggle Similarity results. Coppe docking ate docking and EC scores, using Flare(tm): Doc is offect at that target. EC scores are based on y. Approximate wait time: 5 minutes TARTED ALPHA1 × ALPHA2 × hB1ar atel and the score docking. | king scores are binding energy prediction teh complementarity of ligand and target BETA2 × CAV12 × DPP4 | is and therefore the bigger the negatin and in this case the higher the score, | re energy the more likely the molecu the more likely it is that the molecu |
| Robert Scoffin No Design Set + add teg | NH NH2 ⁺ 0 NH2 ⁺ Idea ∨ | Robert Scoffin No Design Set + add teg | H M M M M M M M M M M M M M | stering ate clustering of the molecule into Inotrope Space a. Approximate wait time: 2 minutes TARTED sulate Clustering rest neighbours in drug-space earest neighbours of the proposed molecule in d 0 minutes TARTED | ce, based on a matrix of simialrities for kr ACE Irug space compare to the Similarity to | nown inotropes. Compounds in the sa | me cluster are likely to hit the same nating false positives in the latter A |
| 0 TD-100332 | OH | OH | | ulate Nearest neighbours in drug-space AR models ate predicted activities of the molecule under im models in Forge(tm) Approximate wait time: 5 TARTED | vestigation using statistical QSAR models minutes | s derived form biological data on knov | vn intropes and inotropic targets. Ba |
| calculated using from Forge(tm) Current Selectic Structure: | g the LeadFinder algori and these can provide on SMILES: COc1ccc(O | thm from within Flare(a prediction of activity CC(F)(F)F)cc1C(=0)N | m). EC is also generated as well as a degree of c C[C@H]1CCC(C)C[NH2+] | using the algorithms from werage, i.e. what is the leve | Flare. 3D-QSAR models | s are generated based | d on the similarity de |
| FFOR NH | | | | es. Results are a raw simil standard deviations away | arity, a number betweei from an average simila | n 0.0 and 1.0, which i rity. Higher is worse, | s then translated int a z-score above 2.0 |
| E Clear Similarity | Molecular similarity of milarity, i.e. what is the score above 3.0 is very ty results Toggle Si | a proposed structure t quality of the prediction significant. Approxim milarity results. | o those of known inotrop on in terms of number of ate wait time: 2 minutes | | | | |
| FFFC, SHA | Molecular similarity of milarity, i.e. what is the score above 3.0 is very ty results Toggle Si | a proposed structure t quality of the prediction significant. Approxim milarity results. | o those of known inotrop on in terms of number of ate wait time: 2 minutes me | Similarity | ♦ Z Score | Shape Sim | 🔶 🛛 Field Sim |

and candidate molecules. This was developed as a companion diagnostic and triaging pre-screen to an *in vitro* myocyte assay from InoCardia for cardiac tox screening. The similarity matrices performed well as a diagnostic tool and allowed for the development of a fail-early strategy in early-stage drug screenings.

References

- 2006, 46 (2), 665-676
- group.com/software/torx/

. Maddock et al, An in vitro platform using the primary cardiomyocyte Work-Loop assay to screen for drug-induced effects on cardiac contractility, Journal of Pharmacological and Toxicological Methods, Volume 105,106759, 2020 2. Cheeseright T., Mackey M., Rose S., Vinter, A.; Molecular Field Extrema as Descriptors of Biological Activity: Definition and Validation. J. Chem. Inf. Model.

3. Flare[™], Cresset[®], Litlington, Cambridgeshire, UK; <u>https://www.cresset-</u> group.com/flare/; Bauer M. R., Mackey M. D.; Electrostatic Complementarity as a Fast and Effective Tool to Optimize Binding and Selectivity of Protein-Ligand Complexes J. Med. Chem. 2019, 62, 6, 3036-3050 4. Torx[®], Torx Software[®], Litlington, Cambridgeshire, UK; <u>https://www.cresset-</u>